Affordable Access

deepdyve-link deepdyve-link
Publisher Website

FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer.

Authors
Type
Published Article
Journal
Journal of Clinical Oncology
1527-7755
Publisher
American Society of Clinical Oncology
Publication Date
Volume
30
Issue
16
Pages
1919–1925
Identifiers
DOI: 10.1200/JCO.2011.38.1095
PMID: 22370325
Source
Medline
License
Unknown

Abstract

Fulvestrant (250 mg + LD regimen) in combination with anastrozole offered no clinical efficacy advantage over anastrozole monotherapy in this population of individuals with a relatively high proportion of previous adjuvant antiestrogen exposure.

Statistics

Seen <100 times